SCHEMBL2014967

SCHEMBL2014967

CON(C)C(=O)c1cc(Cl)c2cccnc2c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.54
ALOX12 P18054 6/20 0.54
HTT P42858 6/20 0.54
KDM4E B2RXH2 5/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
MEN1 O00255 5/20 0.54
MAPT P10636 5/20 0.54
LMNA P02545 4/20 0.54
MMP14 P50281 3/20 0.54
TDP1 Q9NUW8 3/20 0.54
HSP90AA1 P07900 3/20 0.54
ALDH1A1 P00352 3/20 0.54
TP53 P04637 2/20 0.54
CYP3A4 P08684 2/20 0.54
ALOX15 P16050 2/20 0.54
SLC6A2 P23975 2/20 0.54
OPRK1 P41145 2/20 0.54
ALOX15B O15296 1/20 0.54
NR1I2 O75469 1/20 0.54
HTR1A P08908 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2013802 0.80 KDM4E (0.40) KMT2AALOX12HTTKDM4ESMN1; SMN2
SCHEMBL2014457 0.80 ALOX12 (0.64) KMT2AALOX12HTTKDM4ESMN1; SMN2
SCHEMBL2014820 0.79 TRPM8 (0.44) KMT2AALOX12HTTKDM4ESMN1; SMN2
SCHEMBL2015013 0.78 HIF1A (0.44) KMT2AALOX12HTTKDM4ESMN1; SMN2
SCHEMBL4061248 0.78 KDM4E (0.66) KMT2AALOX12HTTKDM4ESMN1; SMN2
SCHEMBL2015993 0.78 SLC40A1 (0.44) KMT2AALOX12HTTKDM4ESMN1; SMN2
SCHEMBL2017299 0.76 ALDH1A1 (0.60) ALDH1A1
SCHEMBL2014720 0.76 ALDH1A1 (0.42) KMT2AALOX12HTTKDM4EMEN1
SCHEMBL257468 0.74 LMNA (0.54) KMT2ASMN1; SMN2MEN1LMNATDP1
SCHEMBL29865799 0.74 LMNA (0.54) KMT2ASMN1; SMN2MEN1LMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS PIK3R1, PIK3R3, PIK3R2 KMT2A 1147/4885ALOX12 1789/4885HTT 2725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.